Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Dyadic International Inc DYAI.OQ DYAI.O is expected to show a rise in quarterly revenue when it reports results on August 12 for the period ending June 30 2026
The Jupiter Florida-based company is expected to report a 2.7% increase in revenue to $993.33 thousand from $967 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dyadic International Inc is for a loss of 4 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dyadic International Inc is $6.00, about 500% above its last closing price of $1.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.04 | -0.04 | -0.05 | Missed | -25 |
Dec. 31 2026 | -0.04 | -0.06 | Missed | -28.9 | |
Sep. 30 2025 | -0.05 | -0.04 | -0.06 | Missed | -38.5 |
Jun. 30 2025 | -0.06 | -0.06 | -0.06 | Met | 0 |
| -0.07 | ||||
Dec. 31 2024 | -0.04 | -0.05 | Missed | -25 | |
Sep. 30 2024 | -0.07 | -0.01 | Beat | 85.7 | |
Jun. 30 2024 | -0.06 | -0.06 | -0.07 | Missed | -7.7 |
This summary was machine generated August 10 at 20:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development